Purpose To investigate serologic evidence of infection by cytomegalovirus (CMV), a herpesvirus with known oncogenic potential that has been detected in malignant prostate tissue, in relation to prostate cancer (PCa) risk in a large case-control study nested in the Prostate Cancer Prevention Trial (PCPT). Methods Cases were men with a confirmed diagnosis of PCa after visit 2 (n = 614), and controls were men not diagnosed with PCa during the trial who also had a negative end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of PCa. Sera from visit 2 were tested for CMV IgG antibodies.
Introduction
Sexually transmitted infections such as herpesviruses have long been hypothesized to contribute to prostate cancer (PCa) risk [1] . Cytomegalovirus (CMV), a common beta herpesvirus, has been detected in pre-malignant and malignant prostate tissue [2] [3] [4] and has been shown to transform cells in vitro [5] and to elicit prostate inflammation [6] , a possible cause of PCa [7] . At the time this study was conceived, a few small observational studies reported suggestive positive findings between CMV and PCa [4, 8, 9] ; however, since these studies were conducted, additional larger studies have observed generally null findings [10] [11] [12] [13] [14] . To further inform the possible role of CMV infection in prostate carcinogenesis, we conducted a large case-control study of CMV serostatus and PCa risk nested within the Prostate Cancer Prevention Trial (PCPT). This study population is especially appropriate for investigations into infections and PCa risk because participants were screened annually for PCa and, if not diagnosed with PCa during the trial, were recommended for ''end-of-study'' prostate biopsy [15] , both of which reduce possible detection bias caused by differential rates of screening by infection status, infection-mediated prostate-specific antigen (PSA) elevation, or infection-mediated induction of any other prostate abnormalities that might trigger a prostate biopsy.
Materials and methods

Study design
The PCPT is a large randomized clinical trial designed to investigate whether the drug, finasteride, a 5a-reductase type II inhibitor, prevents PCa. Generally healthy men C55 years of age who had no evidence of PCa (i.e., PSA concentration B3 ng/mL and a normal digital rectal examination (DRE)) or other clinically significant chronic conditions, including severe benign prostatic hyperplasia (BPH, defined by an International Prostate Symptom Score (IPSS) C20), were recruited at 221 sites across the United States. Between 1994 and 1997, 18,882 of these men were enrolled into the trial and randomized to either the placebo or finasteride arm. At each annual study visit, participants were screened for PCa by DRE and PSA testing, and those found to have abnormal DRE results or elevated PSA ([4 ng/mL) were recommended for prostate biopsy (''forcause'' biopsy). To ensure that approximately equal proportions of men were recommended for biopsy in each arm, PSA concentrations were adjusted among men in the finasteride arm because finasteride is known to lower serum PSA. Serum remaining after PSA testing in both arms was stored for research purposes. After 7 years of participation in the trial, men who had not been diagnosed with PCa were offered a prostate biopsy (''end-of-study'' biopsy) as part of the trial protocol. This biopsy was included to ensure that biopsy referral patterns were not biased by the use of finasteride. Men recommended for biopsy because of an abnormal PSA/DRE that coincided with the ''endof-study'' biopsy window were considered to have had a ''for-cause'' biopsy.
As part of a broader investigation into genetic and other serologic exposures in relation to PCa, we nested a large case-control study within the PCPT. Participants in either treatment arm who had an adequate baseline serum specimen and a definitive positive or negative diagnosis of PCa (i.e., a confirmed PCa diagnosis or a negative ''end-ofstudy'' biopsy) were eligible for inclusion (n = 8,580). We defined cases as men diagnosed with PCa on any ''forcause'' or ''end-of-study'' biopsy (n = 1,809). PCa diagnoses were established by agreement between pathologists at the central laboratory who reviewed all study biopsy material and pathologists at the study sites. Clinical stage was provided by the study sites, and Gleason patterns and sum were determined by central pathology review of biopsy tissue. We defined controls as men not diagnosed with PCa at any time during the trial who also had a negative ''end-of-study'' biopsy. All non-Caucasian men who met this definition were selected as controls to enhance our ability to perform stratified analyses by race/ ethnicity. The remaining controls were selected such that the entire distribution of controls was frequency-matched to cases by age (55-59, 60-64, 65-69, and C70 years), treatment arm, and family history of PCa defined as at least one first-degree relative with PCa (n = 1,809).
We investigated CMV infection in relation to PCa risk in a subset of men from the parent nested case-control study (n = 614 cases and 616 controls). To conserve valuable baseline specimens, we used visit 2 specimens for the CMV analysis and thus chose men with an adequate serum specimen from visit 2. We defined cases as men diagnosed with PCa after visit 2. To allow for investigations between CMV infection and different PCa outcomes with equal precision, we selected approximately equal numbers of cases diagnosed with low-grade (Gleason sum \7) and high-grade (C7) diseases and approximately equal numbers of cases diagnosed by ''for-cause'' and ''end-ofstudy'' biopsy. We defined controls as men not diagnosed with PCa at any time during the trial who also had a negative ''end-of-study'' biopsy. We frequency-matched controls to cases by age, treatment arm, and family history of PCa. Although not specifically selected based on race/ ethnicity, controls were also enriched for non-Caucasian men because of the original parent study's controlsampling scheme.
This study was approved by the Institutional Review Board at Johns Hopkins. The PCPT was approved by the Institutional Review Board at the Fred Hutchinson Cancer Research Center, as well as at each of the institutions that randomized a participant.
Assessment of CMV infection
We assessed the presence of CMV infection, a lifelong viral infection that reactivates periodically from latency throughout life, by measuring IgG antibodies against CMV. CMV IgG seropositivity is believed to be stable and lifelong based on data from longitudinal studies of CMVseropositive individuals [12, 16, 17] , as well as the observed strong positive association between CMV seropositivity and age, with seroprevalence estimates as high as 91 % by C80 years of age [18] .
We performed CMV antibody testing on visit 2 serum using the Captia TM CMV IgG enzyme-linked immunosorbent assay (Trinity Biotech, Berkeley Heights, NJ). In a study conducted by the manufacturer, this assay had a sensitivity of 99.2 % and specificity of 94.1 % relative to another commercially available ELISA and average intrarun, inter-day, and inter-lot coefficients of variation for the immune status ratio (described below) of 5.9, 5.4, and 15.4 %, respectively. We determined serostatus by dividing the optical density for each specimen by the product of the mean optical density of the two calibration specimens included in each run and the lot-specific correction factor to obtain an immune status ratio. We considered specimens with ratios B0.90 to be seronegative, 0.91-1.09 to be equivocal, and C1.10 to be seropositive. We repeated testing for equivocal specimens until a non-equivocal result was obtained (27 tested twice, one tested three times, and four tested four times). We investigated assay reproducibility by testing 12 sets of approximately six blinded replicate samples from serum leftover after routine syphilis testing at the Baltimore Bureau of Disease Control laboratory. Samples were approved for use by the Baltimore City Health Department public review process and anonymized prior to release. Nine of the replicate sets had 100 % agreement, and three had 83.3 % agreement.
Assessment of covariates
At the baseline study visit, PCPT participants completed a detailed self-administered questionnaire on demographic and lifestyle characteristics, including race/ethnicity, education, occupation, marital status, cigarette smoking, physical activity, frequency of sexual activity in the past 4 weeks, histories of vasectomy and diabetes, and current and past regular aspirin use. Height and weight were also measured at the baseline visit. At the 1-year visit, participants completed a 15-page diet and supplement questionnaire designed specifically for PCPT participants that included questions on usual consumption of 99 foods or food groups and nine beverages over the past year, 13 questions on food preparation and purchasing, and three questions on usual consumption of fruits, vegetables, and fried foods. Information on usual intake of energy, protein, carbohydrate, fat, fruit, vegetables, tomato products, red meat, processed meat, fish, calcium and zinc from food and supplements, and alcohol was derived from this questionnaire [19] . Finally, information on treatment for BPH (surgical and medical) was obtained at the baseline, sixmonth, and annual clinic visits and at the three-and ninemonth phone contacts between visits. Information on lower urinary tract symptoms (IPSS) was obtained at recruitment, baseline, and each clinic visit. This information was used to define a history of symptomatic BPH as a report of treatment for BPH or an IPSS [14 at baseline. Military experience was inferred from participants' form of payment (Veterans Affairs-sponsored payment for medical care) and type of study site (Veterans Affairs hospital, Army/ Naval hospital, etc.).
Statistical analysis
To investigate the potential for confounding, we calculated adjusted means and proportions of potential confounding variables by PCa case-control status among all participants and by CMV serostatus among controls. We adjusted means and proportions by age, treatment arm, and family history of PCa to account for frequency-matching and by race to account for over-sampling of non-white Caucasian controls in the study design. We considered as potential confounders all variables mentioned in the covariate section, as well as specimen storage time. To begin to investigate the relation between CMV serostatus and PCa risk, we examined age-, treatment arm-, family history-, and race-adjusted distributions of CMV antibodies by PCa case-control status. Next, we calculated odds ratios (ORs) of PCa by CMV serostatus, using unconditional logistic regression and adjusting for age, treatment arm, family history, and race. We further investigated confounding by adding each potential confounder described above individually to the regression model and comparing the point estimate to that obtained from a model including only age, treatment arm, family history of PCa, and race. No covariates were found to shift the point estimate for CMV serostatus appreciably. To investigate the relation between CMV infection and different PCa outcomes, we performed separate analyses for PCa diagnosed by low-and high-grade cancer, and organ-confined disease. To investigate the potential for detection bias by infection-mediated PSA elevation or induction of prostate abnormalities, we performed additional separate analyses for cases diagnosed by ''for-cause'' and ''end-of-study'' biopsy, and we stratified analyses by follow-up time (within 1 year of blood draw at visit 2 versus later in follow-up, and B2.5 vs.[2.5 years of follow-up from visit 2) for men diagnosed by ''for-cause'' biopsy. We did not perform similar analyses for men diagnosed by ''end-of-study'' biopsy because these cases were diagnosed, by definition, at the end of the study. Finally, to investigate effect modification by age at PCa diagnosis, treatment arm, family history of PCa, race, and past regular aspirin use, we performed further stratified analyses by these covariates. We calculated p values for interaction by the likelihood ratio test.
A priori, we had C80 % power to detect an OR C1.48 for an expected control seroprevalence of approximately 75 % [18] . Statistical analysis was performed using SAS version 9.2 (SAS, Cary, NC).
Results
We selected 616 PCa cases and 616 controls for analysis. Two cases did not have sufficient serum for testing, leaving 614 cases and 616 controls. By study design, 50.7 % of cases were diagnosed with low-grade PCa (Gleason sum\7) and 49.3 % were diagnosed with high-grade (Gleason sum C7) disease. Of cases, 53.3 % were diagnosed by ''for-cause'' biopsy and 46.7 % by ''end-of-study'' biopsy. Almost all cases presented with organ-confined disease (97.6 % of 578 cases with stage information), as expected based on eligibility criteria for the trial (low PSA and normal DRE) and annual PCa screening. The median time from visit 2 to diagnosis was 4.02 years (range 0.02-5.46 years) for cases diagnosed by ''for-cause'' biopsy and 5.02 years (range 4.69-5.44 years) for cases diagnosed by ''end-of-study'' biopsy. Compared to controls, cases were more likely to be Caucasian, as per the study design; not to have military experience; and to report a lesser number of pack-years of smoking. Otherwise, cases and controls were similar with respect to covariates considered. Among controls, CMVseropositive men were more likely to be older and in the finasteride arm; less likely to have a family history of PCa, to be Caucasian, and to have C16 years of education; and more likely to have military experience. Seropositive men also had a higher average body mass index; consumed less overall protein, fish, and calcium; and had smoked a greater average number of pack-years of cigarettes (Table 1) .
Overall, PCa cases and controls had a similar distribution of CMV antibody levels, with the possible exception of a slight, non-significantly higher geometric mean immune status ratio for cases than for the controls. CMV seroprevalence was similar for PCa cases and controls (67.9 vs. 65.2 %, p = 0.31, Table 2 ). No association was observed between CMV serostatus and risk of overall PCa, low-and high-grade PCa, organ-confined disease, and PCa diagnosed by ''for-cause'' and ''end-of-study'' biopsy (Table 3 ). In analyses stratified by follow-up time, a non-significant positive association was observed for men diagnosed by ''for-cause'' biopsy within 1 year of visit 2 (OR = 1.61, 95 % CI 0.75-3.43, n = 38 cases), and a positive association was observed for men diagnosed in the first half of follow-up (OR = 1.67, 95 % CI 1.01-2.76, n = 96 cases). No association was observed for men diagnosed by ''for-cause'' biopsy in the second half of follow-up (OR = 1.03, 95 % CI 0.74-1.42, n = 231 cases). When we excluded cases diagnosed early in follow-up from the entire analysis, no association was observed between CMV serostatus and PCa risk (OR = 1.11, 95 % CI 0.87-1.42, excluding cases diagnosed in the first year of follow-up, and OR = 1.06, 95 % CI 0.83-1.37, excluding cases diagnosed in the first half of follow-up). The slight, non-statistically significant difference in geometric mean immune status ratio between cases and controls also diminished (data not shown). No effect modification was observed by age at PCa diagnosis, treatment arm, family history of PCa, race, or past regular aspirin use (all p-interaction [0.20). Finally, null results were observed in sensitivity analyses defining CMV seropositivity based on the first test result (for originally equivocal results), adjusting for each run, and excluding the one run that yielded two sets of discordant replicate quality control results.
Discussion
In general, no association was observed between CMV serostatus and PCa risk in this large, prospective study. The sole possible exception to this statement was the suggestive positive finding for men diagnosed by ''for-cause'' biopsy early but not later in follow-up. In addition to chance, another possible explanation for this positive finding may be detection bias. Although CMV seropositivity is generally believed to be stable over time, it is possible that, in men with borderline CMV seropositivity, recent (i.e., close in time to visit 2) reinfection with a different CMV strain or reactivation may have led to both a rise in CMV antibody levels at visit 2 and either infection-mediated PSA elevation or infection-mediated prostate abnormalities at visit 2 or subsequent visits, as PSA has been found to remain elevated for at least 6 months following sexually transmitted infectious episodes [20] . Either of these two possibilities might then have triggered a ''for-cause'' prostate biopsy and detection of occult PCa, creating a positive association between CMV antibody seropositivity and PCa among men diagnosed early in follow-up. Thus, in this scenario, results for men diagnosed by ''for-cause'' biopsy early in follow-up would be falsely positive, whereas those for men diagnosed by ''for-cause'' biopsy later in follow-up and those diagnosed by ''end-of-study'' biopsy would be more likely to reflect the true association between CMV serostatus and PCa risk in our study population. As men diagnosed by ''for-cause'' biopsy early in follow-up accounted for only a small proportion of the study population, our overall findings and even those for men diagnosed by ''for-cause'' biopsy were largely uninfluenced by the results for men diagnosed early in follow-up. Our generally null findings for CMV serostatus and PCa risk are consistent with those from most previous, larger studies, three of which observed no association between CMV serostatus and PCa [10, 12, 21] and one of which observed lower CMV antibody levels in PCa cases than controls with BPH [14] . A further two studies detected no CMV DNA in prostate tissue from PCa cases and controls [11] or in only a few participants [13] . Thus, taken together, these findings suggest that CMV infection is not associated with PCa risk.
Although CMV serology is sensitive and specific for CMV infection and CMV antibodies are believed to be stable over time, one possible drawback to measurement of CMV antibodies in studies of CMV infection and prostate carcinogenesis is its inability to indicate when primary infection occurred. In the United States, approximately 30-40 % of children are seropositive for CMV infection by 6-11 years of age, a further 5 % seroconvert during adolescence, and another 45 % go on to acquire CMV infection later in adulthood [18] . Therefore, if, for instance, primary infection during a critical window of susceptibility (e.g., by sexual transmission during adolescence when the infections acquired during this critical window would not be distinguishable from infections acquired outside of this window. The same concern would also be true for tissuebased studies of CMV DNA or RNA. Another possible limitation to both of these types of assessments is their inability to determine when and how often CMV reinfection or reactivation occurred. Therefore, if, for instance, reinfection or reactivation during a critical window of susceptibility is important or the cumulative lifetime frequency of reinfection or reactivation is important, these types of hypothetical associations might also be missed. In summary, findings from our large prospective study of CMV serostatus and PCa risk do not support a role for CMV infection in prostate carcinogenesis. However, we cannot rule out the less likely possibilities of a time-sensitive association between CMV infection and PCa risk or an association between reinfection/reactivation history and PCa risk. a Cases were a sample of men diagnosed with prostate cancer on any biopsy after their second visit or on their end-of-study biopsy (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) b Calculated by logistic regression, including terms for age (continuous), treatment arm, family history of prostate cancer, and non-white race c ''For-cause'' biopsy refers to a biopsy performed because of an elevated prostate-specific antigen concentration or an abnormal digital rectal examination d ''End-of-study'' biopsy refers to a biopsy performed without indication after 7 years of participation in the study as per trial protocol
